Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II)

Kidney International

Volumn 70, Issue 1, 2006, Pages 42-50

  Licht, C ^a   Heinen, S ^b   Jozsi M ^b   Loschmann I ^b   Saunders, R E ^c   Perkins, S J ^c   Waldherr, R ^d   Skerka, C ^b   Kirschfink, M ^e   Hoppe, B ^a   Zipfel, P F ^b,f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b HANS KNÖLL INSTITUTE   (Germany)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d Institute for Clinical Pathology   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Complement; Hemolytic uremic syndrome; Membranoproliferative glomerulonephritis (MPGN), Factor H, alternative complement pathway

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; DECAY ACCELERATING FACTOR; FRESH FROZEN PLASMA; LYSINE; MUTANT PROTEIN; REGULATORY DOMAIN 4 PROTEIN; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; COMPLEMENT ALTERNATIVE PATHWAY; CONTROLLED STUDY; DENSE DEPOSIT DISEASE; DISEASE COURSE; FEMALE; GENE LOCATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; PATHOPHYSIOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SCHOOL CHILD; SEQUENCE HOMOLOGY; WILD TYPE;

AMINO ACID SEQUENCE; CHILD; COMPLEMENT C3 NEPHRITIC FACTOR; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; CONSANGUINITY; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; LYSINE; MOLECULAR SEQUENCE DATA; PEDIGREE; PLASMA; PROTEIN STRUCTURE, TERTIARY; SEQUENCE DELETION;

EID: 33745697887     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000269     Document Type: Article

References (48)

1. Davison AM. Oxford Textbook of Clinical Nephrology. Oxford University Press: Oxford, 2005.
2. Ault BH. Factor H and the pathogenesis of renal diseases. Pediatr Nephrol 2000; 14: 1045-1053.
3. Thompson RA, Winterborn MH. Hypocomplementaemia due to a genetic deficiency of beta 1H globulin. Clin Exp Immunol 1981; 46: 110-119.
4. Wyatt RJ, Julian BA, Weinstein A et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. J Clin Immunol 1982; 2: 110-117.
5. Levy M, Halbwachs-Mecarelli L, Gubler MC et al. Human complement factor H deficiency associated with hemolytic uremic syndrome. Kidney Int 1986; 30: 949-956.
6. Nielsen HE, Christensen KC, Koch C et al. Scand J Immunol 1989; 30: 711-718.
7. Rougier N, Kazatchkine MD, Rougier JP et al. Am Soc Nephrol 1998; 9: 2318-2326.
8. Fijen CA, Kuijper EJ, Te Bulte M et al. Heterozygous and homozygous factor H deficiency states in a Dutch family. Clin Exp Immunol 1996; 105: 511-516.
9. Brai M, Misiano G, Maringhini S et al. Combined homozygous factor H and heterozygous C2 deficiency in an Italian family. J Clin Immunol 1988; 8: 50-56.
10. Vogt BA, Wyatt RJ, Burke BA et al. Inherited factor H deficiency and collagen type III glomerulopathy. Pediatr Nephrol 1995; 9: 11-15.
11. Dragon-Durey MA, Fremeaux-Bacchi V, Loirat C et al. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J Am Soc Nephrol 2004; 15: 787-7959.
12. Meri S, Koistinen V, Miettinen A et al. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J Exp Med 1992; 175: 939-950.
13. Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116: 1-7.
14. Mathieson PW, Wurzner R, Oliveria DB et al. Complement-mediated adipocyte lysis by nephritic factor sera. J Exp Med 1993; 177: 1827-1831.
15. West C. Complement and glomerular Diseases. In: Volonakis JE, Frank MM (eds). The Human Complement System in Health and Disease. M. Dekker, Inc., New York, 1998, pp. 571-596.
16. Hogasen K, Jansen JH, Mollnes TE et al. Hereditary porcine membrano-proliferative glomerulonephritis type II is caused by factor H deficiency. J Clin Invest 1995; 95: 1054-1061.
17. Pickering MC, Cook HT, Warren J et al. Uncontrolled C3 activation causes membranoproliferative, glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002; 31: 424-428.
18. Ault BH, Schmidt BZ, Fowler NL et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997; 272: 25168-25175.
19. Hegasy GA, Manuelian T, Hogasen K et al. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002; 161: 2027-2034.
20. Schwertz R, Rother U, Anders D et al. Complement analysis in children with idiopathic membranoproliferative glomerulonephritis: a long-term follow-up. Pediatr Allergy Immunol 2001; 12: 66-172.
21. Spitzer RE, Stitzel AE, Tsokos GC. Human antiidiotypic antibody responses to autoantibody against alternative pathway C3 convertase. Clin Immunol Immunopathol 1990; 57: 19-32.
22. Caprioli J, Bettinaglio P, Zipfel PF et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12: 297-307.
23. Neumann HP, Salzmann M, Bohnert-Iwan B et al. Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries. J Med Genet 2003; 40: 676-681.
24. Kuhn S, Zipfel PF. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur J Immunol 1996; 10: 2383-2387.
25. Kuhn S, Skerka C, Zipfel PF. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H. J Immunol 1995; 155: 5663-5670.
26. Gordon DA, Kaufman R, Blackmore T et al. Identification of complement regulatory domains in human factor H. J Immunol 1995; 155: 348-356.
27. Atkinson JP. Complement system on the attack in autoimmunity. J Clin Invest 2003; 112: 1639-1641.
28. Jozsi M, Manuelian T, Heinen S et al. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: relevance for pathology. Histol Histopathol 2004; 19: 251-258.
29. Casasnovas J, Larvie M, Stehle T. Crystal structure of two CD46 domains reveals an extended measles virus- binding surface. EMBO J 1999; 18: 2911-2929.
30. Bouma B, de Groot P, van den Elsen J et al. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-5175.
31. Licht C, Weyersberg C, Heinen S et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005; 45: 415-421.
32. Filler G, Radhakrishnan S, Strain L et al. Challenges in the management of infantile factor H associated hemolytic uremic syndrome. Pediatr Nephrol 2004; 19: 908-911.
33. Mayer MM. On the destruction of erythrocytes and other cells by antibody and complement. Cancer Res 1961; 21: 1262-1269.
34. Joiner KA, Hawiger A, Gelfand JA. A study of optimal reaction conditions for an assay of the human alternative complement pathway. Am J Clin Pathol 1983; 79: 65-72.
35. Friese MA, Manuelian T, Junnikkala S et al. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin Exp Immunol 2000; 121: 406-415.
36. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Meth 1982; 51: 101-107.
37. Leitao MF, Vilela MM, Rutz R et al. Complement factor I deficiency in a family with recurrent infections. Immunopharmacology 1997; 38: 207-213.
38. Skerka C, Hellwage J, Weber W et al. The human factor H-related protein 4 (FHR-4). A novel short consensus repeat-containing protein is associated with human triglyceride-rich lipoproteins. J Biol Chem 1997; 272: 5627-5634.
39. Manuelian T, Hellwage J, Meri S et al. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-1190.
40. Jokiranta TS, Hellwage J, Koistinen V et al. Each of the three binding sites on complement factor H interacts with a distinct site on C3b. J Biol Chem 2000; 275: 27657-27662.
41. Meri T, Hartmann A, Lenk D et al. The yeast Candida albicans binds complement regulators factor H and FHL-1. Infect Immun 2002; 70: 5185-5192.
42. Bateman AL, Coin R, Durbin RD et al. The Pfam Protein Families Database. Nucl Acids Res 2004; 32: D138-D141.
43. Higgins D, Thompson J, Gibson T. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucl Acids Res 1994; 22: 4673-4680.
44. Norman DG, Barlow PN, Baron M et al. Three-dimensional structure of a complement control protein module in solution. J Mol Biol 1991; 219: 717-729.
45. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-2637.
46. Laskowski RA, MacArthur MW, Moss DS et al. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Cryst 1993; 26: 283-291.
47. Murshudov G, Vagin A, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Cryst 1997; D53: 240-255.
48. Kraiczy P, Hellwage J, Skerka C et al. Complement resistance of Borrelia burgdorferi correlates with the expression of BbCRASP-1, a novel linear plasmid-encoded surface protein that interacts with human factor H and FHL-1 and is unrelated to Erp proteins. J Biol Chem 2004; 279: 2421-2429.